CELLINK BIOPRINTING AB

Their core work

CELLINK BIOPRINTING AB is a Swedish bioprinting technology company based in Gothenburg that develops and applies 3D bioprinting systems, bioinks, and biofabrication processes for biomedical research applications. In EU research consortia, they contribute their bioprinting hardware and materials expertise — including collagen and gelatin-based bioinks — to produce living tissue constructs for regenerative medicine and pharmaceutical testing. Their technology bridges the gap between laboratory biology and functional tissue: they print cells and growth factors into geometrically precise scaffolds that mimic real tissue architecture. This makes them a rare industrial partner capable of translating research-grade bioprinting into reproducible, application-ready biological models.

What they specialise in

How they've shifted over time

CELLINK entered H2020 with a clear focus on structural tissue repair — ankle joints, tendons, and osteochondral injuries — where their bioprinting technology produces personalized patient-specific scaffolds. Their second project marks a pivot toward pharmaceutical safety and regulatory science: instead of building tissue to implant, they build tissue to test drugs on, specifically for pregnancy and fetal toxicology. This reflects a broader industry trend in which bioprinting companies expand from regenerative medicine into organ-on-a-chip and safety testing markets. The emergence of 'biodigital twin' and 'pharmacovigilance' in their recent keyword set signals they are moving toward computational integration alongside physical bioprinting.

CELLINK is expanding their platform from implantable tissue constructs into regulatory-grade in vitro testing models, positioning themselves at the intersection of bioprinting, toxicology, and digital biology — a direction with strong commercial pull from pharma and chemical industry clients.

How they like to work

CELLINK participates exclusively as a partner rather than a consortium leader, which is consistent with their role as an industrial technology provider supplying specialized hardware and materials to academic-led research projects. Despite only two projects, they have accumulated 31 unique consortium partners across 13 countries, suggesting they operate within large multi-partner consortia rather than small bilateral collaborations. This pattern indicates they are a sought-after specialist contributor — brought in for their unique bioprinting capabilities — rather than a project architect.

With 31 unique partners across 13 countries from just two projects, CELLINK operates within broad, international research networks typical of large RIA consortia. Their European reach spans well beyond Sweden, though the specific partner countries are not available to determine regional concentration.

What sets them apart

CELLINK is one of very few industrial bioprinting companies to participate directly in EU-funded research consortia, making them a bridge between commercial bioprinting product development and academic research pipelines. Unlike university labs that use bioprinting as one method among many, CELLINK's entire business model centers on biofabrication — giving them depth in bioink formulation, printer optimization, and reproducibility that academic partners rarely possess. For consortium builders, they offer not just technology access but also a commercialization pathway: findings developed in EU projects can move toward CELLINK's existing product lines and customer base in the life sciences industry.

Highlights from their portfolio

• LIFESAVER
  The largest of their two projects (EUR 423,112) and the most ambitious in scope — applying bioprinting to construct placental models for chemical safety and pharmacovigilance, a highly specialized regulatory application with direct relevance to EU chemicals legislation.
• TRiAnkle
  Demonstrates CELLINK's core regenerative medicine expertise: personalized 3D bioprinted scaffolds for ankle joint repair covering multiple injury types (tendon rupture, osteochondral defects), combining nanoencapsulation and bioreactor validation.